eligibility_summary
Include: Untreated MZL needing systemic therapy (nodal/splenic/extranodal, gastric only if advanced) or untreated FL grade 1–3a, path-confirmed CD20+ disease with measurable lesion ≥1.5 cm, age ≥18, ECOG 0–2, adequate organs. Exclude: prior lymphoma therapy/BTKi/rituximab allergy, transformed/CNS disease, bleeding disorder/warfarin, CYP3A inhibitors/inducers, active infection incl. HIV, HBV DNA+, HCV RNA+, recent live vaccine, major CV disease/stroke/uncontrolled HTN, recent surgery.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, open-label trial testing rituximab plus zanubrutinib in untreated indolent B‑cell lymphomas (marginal zone and follicular). Interventions: 1) Rituximab—type I anti‑CD20 monoclonal antibody (biologic), depletes CD20+ B cells via ADCC, CDC, and apoptosis, given IV or SC (Hycela). 2) Zanubrutinib—covalent, irreversible small‑molecule Bruton’s tyrosine kinase (BTK) inhibitor, suppresses B‑cell receptor signaling and downstream NF‑κB/PI3K pathways to reduce B‑cell survival and proliferation. Targets: CD20+ malignant B cells, BTK/BCR signaling pathway.